Merz North America
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merz North America sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
Merz North America: 35 sponsored US clinical trials, 1 recruiting.
Merz North America sponsors 35 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 31 completed. 15 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Volume Loss in the Dorsum of the Hand, with 2 trials.
Top-decile sponsor footprint
Merz North America ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
35 total, page 1 of 1
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193
A Study to Determine if RADIESSE® Dilute Treatment in Décolleté of Adult Women Affects Radiographic Imaging Assessments
NCT07086248
Longitudinal Evaluation and Real-world Evidence of NT201
NCT05222607
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
NCT05784363
Evaluation of the Effectiveness and Safety of Diluted RADIESSE® in the Treatment of Décolleté Wrinkles
NCT05163353
Effectiveness and Safety of the Octave System for Lifting the Eyebrow and Improving the Appearance of the Face and Neck
NCT05067504
A Study of Octave System for Improving Lines and Wrinkles of the Décolleté
NCT04681352
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
NCT04594213
Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow
NCT04594239
A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital Hollow
NCT03777917
Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline
NCT03583359
Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds
NCT03319719
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
NCT03351335
Radiesse® Safety Study For the Treatment of Hands
NCT02904096
Radiological Evaluation of Radiesse Implantation in the Hands
NCT02949921
Neurogenic Dysphonia/Dysphagia Registry
NCT02493491
Pediatric Subjects With Tinea Corporis
NCT02227290
The Treatment of Glabellar Frown Lines
NCT02096081
An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis
NCT02466867
Evaluation of Radiesse® Dermal Filler for Hand Treatment
NCT01832090
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
NCT01712360
Study of the Cabochon System for Improvement in the Appearance of Cellulite
NCT01671839
Belotero Post Approval Study
NCT01635855
Mederma to Reduce Appearance of Post Surgical Scars
NCT01504061
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
NCT01290341
Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
NCT01289015
Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States
NCT01287247
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
NCT00922623
Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler
NCT01012661
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
NCT00750152
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
NCT00750139
This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence
NCT00996489
Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft
NCT00877279
Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
NCT01012388
Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.
NCT00876265
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 8 |
| Phase 4 | 7 |
Therapeutic Areas
Where Merz North America enrollment is open (later-stage tilt)
1 recruiting of 35 indexed (3% open); 31 completed (89%).
Phase mix: 15 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Volume Loss in the Dorsum of the Hand (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merz North America: open-pipeline peers nationwide
Peers matched on 35 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Merz North America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 trials (± recruiting share)
- ACADIA Pharmaceuticals · 35 trials · 9% recruiting
- INSYS Therapeutics · 35 trials · 0% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
- Philips Respironics · 35 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- VIVUS · 3% recruiting · 35 trials
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
Related
What to do with this Merz North America page
35 registered trials is a research-attention snapshot, not an endorsement of Merz North America or any single study.
- 1 of Merz North America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Volume Loss in the Dorsum of the Hand is the condition Merz North America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Volume Loss in the Dorsum of the Hand trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merz North America pipeline card: 35 registered trials from official public datasets.Report a data error.